For Christopher J. Schaber, successfully helming Soligenix Inc. involves walking a tightrope between developing a roster of promising drugs and raising the funds to pay for it. Recently listed on NASDAQ, Soligenix is a late-stage biopharmaceutical…
A small clinical stage biopharmaceutical company in the Northeast, which specializes in developing novel antibiotics to be effective against serious and life-threatening infections, was growing and needed extra financial support in the…
In the life sciences industry, clinical trials can be both exciting and daunting to embark on. When approaching clinical trials your science is already down pat, so new professionals and expertise are often needed for the next phase of develop…
Roche, Novo Nordisk and Regeneron represent the pharmaceutical industry in FORTUNE‘s annual “100 Best Companies to Work For” list in 2017. Google, Wegmans and Boston Consulting Group took the top three…
CRISPR Therapeutics reports that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology. The European patent application received many third…
U.S. pharma brands jumped in value in Brand Finance’s annual report of the nation’s 500 most valuable brands, with the exception of Valeant Pharmaceuticals. Brand value is different from reputation, which is…
Alphabet company Calico and biotech startup C4 Therapeutics (C4T) join forces to tackle age-related diseases including cancer. This collaboration will use C4T’s expertise to discover small molecule candidates. Calico will then…
When: April 27, 2017
Where: Philadelphia, PA Digitizing the Enterprise – The Future is Now
Technology moves at an exponential pace and traditional organizations do not. True leaders cannot get left behind the digital curve.
Former FDA commissioner Robert Califf, who will likely be replaced by Scott Gottlieb as the new commissioner, has become the chair of the newly formed nonprofit called People-Centered Research…
GlaxoSmithKline CEO Andrew Witty has stepped down, passing the role to successor Emma Walmsley. This transition marks the end of his 9-year tenure at the company. Witty wasn’t afraid to take chances as a leader…
At the very core of Ashton Tweed’s talent-acquisition and talent-placement business is a robust professional force of highly experienced life sciences industry experts. These uniquely talented professionals are deployed throughout Ashton Tweed’s diverse range of service offerings to solve our clients’ human capital and management needs.
